Therapeutic Antibodies

Melanoma
#Aulos Bioscience #Melanoma #Monoclonal antibodies #Oncology #Phase II trial

Aulos doses first patient in Phase II cohort for melanoma treatment

Aulos Bioscience has dosed its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma.   The new cohort forms part of the company’s Phase I/II clinical trial of AU-007… Read More

#Cancer Research #News

Lecanemab
#Alzheimer's #Biogen #Eisai #European Commission #Monoclonal antibodies #Neuroscience

Lecanemab gets EU approval in early Alzheimer’s

The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU).  The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU.  Lecanemab is indicated for… Read More

#News #Regulatory #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Dementia #Therapeutic Antibodies #UK Dementia Research Institute

Scientists discover why Alzheimer’s drugs are effective

Scientists in the UK and Belgium have discovered new insights into how four different anti-amyloid drugs interact with amyloid beta protein, revealing why the drugs have had varying levels of success at treating Alzheimer’s disease. Amyloid beta is one of the toxic proteins which builds up in clumps… Read More

#News #Trending News

#3D modelling #Artificial intelligence (AI) #European Commission #Monoclonal antibodies #Oncology #Solid tumours

This week in drug discovery (7-11 April) 

News round-up for 7-11 April by DDW Senior Digital Content Editor Diana Spencer. As the political news brings more uncertainty for the sector, this week we are focusing on positive developments in the field of oncology, from the possibilities of cancer cures in the rainforest, to a new… Read More

#News

Human antibodies
#Antibodies #Epsilogen #Mergers and acquisitions #Oncology #Therapeutic Antibodies

Acquisition creates leading pan-isotype cancer antibody company

Epsilogen has completed the acquisition of TigaTx, a biotechnology company developing engineered immunoglobulin A (IgA) antibodies.  As a result, US-based TigaTx will become a wholly owned subsidiary of Epsilogen. Dr Sonia Gulati, a Principal at Global BioAccess Fund, has joined the Epsilogen Board of Directors. … Read More

#Business & Investment #News

Meet The Exhibitor
#AI / data analytics / healthtech / informatics #Antibodies #Cancer research #Career #From the top #Genetics / genomics #Interview #Meet the Researcher #Oncology #Research and development #Sitting Down With #Women in STEM

New podcast: Getting to know key drug discovery leaders

This is the latest episode of the free DDW narrated podcast, titled “Getting to know key drug discovery leaders”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Sitting down with… Neil Dhawan”, “Meet the researcher: Giusy Di Conza, iOnctura”… Read More

#News

European Commission
#European Commission #Johnson & Johnson #Monoclonal antibodies #Oncology

EC approves subcutaneous use of J&J antibodies for cancer

The European Commission (EC) has approved an indication extension for two of Johnson & Johnson’s monoclonal antibody therapies in oncology.  The approval of Darzalex (daratumumab) has been extended to include a subcutaneous (SC) formulation in the frontline setting in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for… Read More

#News #Regulatory

#Alzheimer's #Antibody drug conjugate (ADC) #hepatitis #Monoclonal antibodies #Oncology #Therapeutic Antibodies

This week in drug discovery (31 March – 4 April) 

News round-up for 31 March – 4 April by DDW Senior Digital Content Editor Diana Spencer. The headlines this week have demonstrated the importance of antibody therapies, particularly in treating cancer, but also as potential therapeutics for a range of other diseases including hepatitis D and Alzheimer’s. Read More

#News

Therapeutic antibodies
#Alzheimer's #Antibodies #Cancer #Covid-19 #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies #Rare disease #Therapeutic Antibodies

Podcast: Where is the innovation in the therapeutic antibody market?

This is the latest episode of the free DDW narrated podcast, titled “Where is the innovation in the therapeutic antibody market?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases… Read More

#News

Bladder cancer
#AstraZeneca #Bladder cancer #FDA #Monoclonal antibodies #Oncology

Imfinzi approval a ‘breakthrough’ for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).  It is approved in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy… Read More

#News #Regulatory

Monoclonal antibody
#Bluejay Therapeutics #Clinical trial #hepatitis #Monoclonal antibodies #Viral hepatitis

Trial investigates monoclonal antibody for chronic hepatitis D

Bluejay Therapeutics’ AZURE-1 global pivotal clinical trial evaluating brelovitug (BJT-778) for the treatment of chronic hepatitis D (CHD) has dosed its first patient.   Brelovitug is an investigational fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the hepatitis D virus… Read More

#News

#Helicore Biopharma #Monoclonal antibodies #Obesity #Phase I trial #Weight loss

First-in-class GIP antagonist for obesity enters Phase I trials

Helicore Biopharma has reported dosing the first participant in its Phase I study of HCR-188 for the treatment of obesity.   HCR-188 is a first-in-class monoclonal antibody (mAb) designed to bind to circulating glucose-dependent insulinotropic peptide (GIP) ligand, unlike antibodies that bind the GIP receptor (GIP… Read More

#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Drivers and challenges in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Monoclonal antibody
#Antibodies #Drug discovery #Immunology / Virology & Vaccines #Therapeutic Antibodies

Antibody therapies: A core technology of the past, present, and the future

Jeff Fischer, President of Longhorn Vaccines & Diagnostics, discusses the evolution of antibody therapies from early serum treatments to targeted monoclonal antibodies, their impact on disease prevention and treatment, and the growing acceptance of antibody-based alternatives to traditional vaccines. Antibody therapy has been used to prevent and treat disease for over… Read More

#Exclusive Content